Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry

NCT05299437 is registered in ClinicalTrials.gov with Carlo Chiesa as lead sponsor.

NCT NCT05299437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05299437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Therapy of Metastatic Thyroid Cancer: Biological Characterization and Optimization With 124I PET Dosimetry
Lead sponsor
Carlo Chiesa
Phase
Phase 2
Overall status
Unknown status
Start date
May 12, 2021
Completion date
September 30, 2024
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic differentiated thyroid cancer